1,2 PTLD are virtually always of B cell origin; PTLD of T cell origin is rare.
Post-transplant lymphoproliferative disorders (PTLD) are a serious complication that occur in immunocompromised recipients of solid organ and allogeneic hematopoietic cell transplants (HCT).
1,2 PTLD are virtually always of B cell origin; PTLD of T cell origin is rare. [3] [4] [5] Also, while B cell PTLD are usually associated with Epstein-Barr virus (EBV) infection, most T cell PTLD are not associated with the EBV genome. [3] [4] [5] Three cases of T cell PTLD have been reported as occurring after allogeneic HCT, all unassociated with EBV infection; 3 T cell PTLD after autologous HCT has not been reported. We describe an unusual case of T cell lymphoproliferation following autologous blood stem cell transplantation (ABSCT), in which DNA studies in the tumor cells demonstrated a monoclonal proliferation of T cells infected with EBV. 
Case report
A 48-year-old male with bilateral cervical lymphadenopathy was diagnosed in 1992 with Hodgkin's disease (lymphocyte-rich classical type; clinical stage IIA). The patient achieved remission with doxorubicin-based chemotherapy, but the cervical lymphadenopathy recurred 2 years later. A repeat lymph node biopsy yielded a specimen with a histologic appearance similar to that at presentation. No rearrangements of the T cell receptor ␤ (TCR␤) or immunoglobulin heavy chain (IgH) genes were seen. After harvesting of blood stem cells mobilized by high-dose Ara-C and G-CSF (filgrastim), the patient underwent ABSCT and entered a second remission. (Figure 1a) . No rearrangement of the IgH gene was seen. Southern blot analysis of the EBV terminal repeat gene clearly showed that the atypical lymphocytes were clonally infected by an episomal form of EBV (Figure 1b) . Despite administration of ganciclovir, aciclovir, ␥-globulin, and vinblastine, abdominal lymphadenopathy and fever persisted. The patient died of septic shock 9 months after admission. Permission for autopsy was not granted. 
Discussion
The presence of a clonal EBV strain infecting CD8 + T cells during the course of fatal infectious mononucleosis has been described. 6 This probably was not the situation in our patient, since infectious mononucleosis is caused principally by a first infection with EBV, and the pattern of antibodies against EBV prior to ABSCT in this patient indicated that previous infection with EBV had occurred. Clonal lymphocytosis may occur after allogeneic and autologous HCT, possibly associated with known or unknown infections. Thus, the clonal expansion of CD8 + T cells in our patient may have been a reaction to agents other than EBV. From this point of view, the clonality pattern of EBV infection could have resulted simply from coincidental latent EBV infection of CD8 + T cells that clonally expanded in response to an exogenous stimulus. However, EBV was detected not only in clonal CD8
+ T cells but also in lymph node tissue and serum. This indicates that the EBV had reactivated, and the reactivation caused clonal CD8
+ T cell proliferation in our patient.
Although monoclonal lymphoproliferation was not evident in the patient's mesenteric lymph nodes, the atypical lymphocytes in the blood appeared to represent a monoclonal proliferation of EBV-infected CD8 + T cells. PTLD can occur as a polyclonal, oligoclonal, or monoclonal proliferation of lymphoid cells. 7 An interval of 4 months separated the biopsy of the mesenteric lymph nodes and the appearance of atypical lymphocytes in the peripheral blood in our patient. Early in the course of PTLD, proliferation of EBV-infected cells in the lymph nodes may have been polyclonal, while subsequent genetic changes may have resulted in monoclonal proliferation. 7 Alternatively, events in this patient may have been similar to those in patients with a severe chronic active EBV infection, where a monoclonal proliferation of EBV-infected T cells may be detected in the blood even when no evidence of lymphoma exists. 8 The EBV-associated T cell lymphoproliferation seen in our patient may have been related to underlying Hodgkin's disease, which is known to cause immunodeficiency. However, no persistence or recurrence of Hodgkin's disease was demonstrated on histologic examination of lymph node biopsy specimens. Therefore, the disease was considered to be related to an immunodeficient state cause by ABSCT per se.
Several cases of EBV-associated PTLD following autologous HCT have been reported, but all involved B cells. [9] [10] [11] [12] [13] [14] These included cases where in vitro purging of the bone marrow with anti-T cell antibodies was performed, 9, 12 or where a CD34-purified graft was infused; 13 this suggests that T cell depletion of the graft increases the risk for developing PTLD after autologous HCT, as is the case after allogeneic HCT. 2 However, PTLD has occurred in cases where no purging was carried out, 11, 14 or where only anti-B cell antibodies were used for purging. 10 The present case of T cell PTLD developed after an ABSCT where the graft contained abundant T cells. The specific risk factors associated with PTLD following autologous HCT remain to be defined.
The prognosis of T cell PTLD, whether associated with EBV infection or not, appears to be generally poor. [3] [4] [5] Our patient did not respond to antiviral agents, ␥-globulin, or a chemotherapeutic agent. Donor T cell infusion has been reported to be effective for treating EBV-associated B cell PTLD after allogeneic HCT. 1, 2 Whether analogous approaches could be effective against EBV-associated T cell PTLD remains to be clarified.
